Menu
Back to Journals » OncoTargets and Therapy » Volume 6
New and emerging treatment options for biliary tract cancer
Received 29 May 2013
Accepted for publication 10 July 2013
Published 30 October 2013 Volume 2013:6 Pages 1545—1552
DOI https://doi.org/10.2147/OTT.S32545
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 6
Marcus S Noel, Aram F Hezel
James P Wilmot Cancer Center, University of Rochester, Rochester, NY, USA
Abstract: Biliary tract cancer (BTC) is a group of relatively rare tumors with a poor prognosis. The current standard of care consists of doublet chemotherapy (platinum plus gemcitabine); however, even with cytotoxic therapy, the median overall survival is less than 1 year. The genetic basis of BTC is now more clearly understood, allowing for the investigation of targeted therapy. Combinations of doublet chemotherapy with antiepidermal growth factor receptor agents have provided modest results in Phase II and Phase III setting, and responses with small molecule inhibitors are limited. Moving forward as we continue to characterize the genetic hallmarks of BTC, a stepwise, strategic, and cooperative approach will allow us to make progress when developing new treatments.
Keywords: biliary tract cancer, cholangiocarcinoma, genetics, targeted therapy
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.